Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report

Ramsey, Scott D.; Willke, Richard J.; Briggs, Andrew; Brown, Ruth E.; Buxton, Martin; Chawla, Anita; Cook, J.R.; Glick, Henry A.; Liljas, Bengt; Petitti, Diana B.; Reed, Shelby D.

doi:10.1111/j.1524-4733.2005.00045.x

Cited by 603 publications

(562 citation statements)

References 87 publications

Supporting

Mentioning

550

Contrasting

Unclassified

Order By: Relevance

“…We conducted the sensitivity analyses at 12‐month follow‐up because a longer follow‐up measurement is more likely to capture long‐term effects of the intervention (Ramsey et al., 2005). First, we repeated the analyses using the human capital approach (HCA) to value productivity losses (SA1).…”

Section: Methodsmentioning

confidence: 99%

Cost effectiveness of guided Internet-based interventions for depression in comparison with control conditions: An individual-participant data meta-analysis

Kolovos

Dongen²,

Riper

et al. 2018

Depress Anxiety

View full text Add to dashboard Cite

BackgroundThere is limited evidence on the cost effectiveness of Internet‐based treatments for depression. The aim was to evaluate the cost effectiveness of guided Internet‐based interventions for depression compared to controls.MethodsIndividual–participant data from five randomized controlled trials (RCT), including 1,426 participants, were combined. Cost‐effectiveness analyses were conducted at 8 weeks, 6 months, and 12 months follow‐up.ResultsThe guided Internet‐based interventions were more costly than the controls, but not statistically significant (12 months mean difference = €406, 95% CI: − 611 to 1,444). The mean differences in clinical effects were not statistically significant (12 months mean difference = 1.75, 95% CI: − .09 to 3.60 in Center for Epidemiologic Studies Depression Scale [CES‐D] score, .06, 95% CI: − .02 to .13 in response rate, and .00, 95% CI: − .03 to .03 in quality‐adjusted life‐years [QALYs]). Cost‐effectiveness acceptability curves indicated that high investments are needed to reach an acceptable probability that the intervention is cost effective compared to control for CES‐D and response to treatment (e.g., at 12‐month follow‐up the probability of being cost effective was .95 at a ceiling ratio of 2,000 €/point of improvement in CES‐D score). For QALYs, the intervention's probability of being cost effective compared to control was low at the commonly accepted willingness‐to‐pay threshold (e.g., at 12‐month follow‐up the probability was .29 and. 31 at a ceiling ratio of 24,000 and 35,000 €/QALY, respectively).ConclusionsBased on the present findings, guided Internet‐based interventions for depression are not considered cost effective compared to controls. However, only a minority of RCTs investigating the clinical effectiveness of guided Internet‐based interventions also assessed cost effectiveness and were included in this individual–participant data meta‐analysis.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost effectiveness of guided Internet-based interventions for depression in comparison with control conditions: An individual-participant data meta-analysis

Kolovos

Dongen²,

Riper

et al. 2018

Depress Anxiety

View full text Add to dashboard Cite

show abstract

“…15,16 Inpatient and ED costs were determined using a two-part model because many participants incurred no costs. 13,17,18 The first part estimated the probability of having a positive cost using a logistic regression model, and the second part estimated cost in participants whose cost was positive using GLM with gamma distribution and log link. The unconditional predicted cost was obtained by multiplying the probability and the expected cost.…”

Section: Discussionmentioning

confidence: 99%

Cost Comparison Between Home Telemonitoring and Usual Care of Older Adults: A Randomized Trial (Tele-ERA)

Upatising

Wood

Kremers

et al. 2015

Telemedicine and e-Health

View full text Add to dashboard Cite

Background: From 1992 to 2008, older adults in the United States incurred more healthcare expense per capita than any other age group. Home telemonitoring has emerged as a potential solution to reduce these costs, but evidence is mixed. The primary aim of the study was to evaluate whether the mean difference in total direct medical cost consequence between older adults receiving additional home telemonitoring care (TELE) (n = 102) and those receiving usual medical care (UC) (n = 103) were significant. Inpatient, outpatient, emergency department, decedents, survivors, and 30-day readmission costs were evaluated as secondary aim. Materials and Methods: Multivariate generalized linear models (GLMs) and parametric bootstrapping method were used to model cost and to determine significance of the cost differences. We also compared the differences in arithmetic mean costs. Results: From the conditional GLMs, the estimated mean cost differences (TELE versus UC) for total, inpatient, outpatient, and ED were -$9,537 (p = 0.068), -$8,482 (p = 0.098), -$1,160 (p = 0.177), and $106 (p = 0.619), respectively. Mean postenrollment cost was 11% lower than the prior year for TELE versus 22% higher for UC. The ratio of mean cost for decedents to survivors was 2.1:1 (TELE) versus 12.7:1 (UC). Conclusions: There were no significant differences in the mean total cost between the two treatment groups. The TELE group had less variability in cost of care, lower decedents to survivors cost ratio, and lower total 30-day readmission cost than the UC group.

show abstract

“…These 2 chemotherapy regimens were evaluated as described separately in a prospective, phase 2 randomized controlled trial with regard to PFS and QoL 4 ; costs were not collected during the clinical trial but were obtained as described below using national reimbursement data. 5 Investigators were required to obtain approval from their respective institutional review boards; the trial was registered in the clinical trials database of the United States National Institutes of Health (National Clinical Trials no. 00090610).…”

Section: Methodsmentioning

confidence: 99%

Cost‐effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum‐sensitive, recurrent ovarian cancer

Havrilesky¹,

Pokrzywinski²,

Revicki³

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND:In a randomized controlled trial (RCT) of patients with recurrent, platinum-sensitive ovarian cancer, the combination weekly docetaxel and carboplatin was associated a with progression-free survival (PFS) of 13.7 months compared with 8.4 months for sequential, single-agent docetaxel followed by carboplatin. The objective of the current study was to construct a cost-utility model to compare these 2 regimens with the incorporation of prospectively collected quality-of-life (QoL) data. METHODS: An RCT of concurrent docetaxel and carboplatin (cDC) versus docetaxel followed by carboplatin (sequential docetaxel and carboplatin [sDC]) was the basis for a Markov decision model, and the primary effectiveness outcome was PFS. Costs were estimated using US dollars based on Medicare reimbursements for chemotherapy regimens, bone marrow support, and management of adverse events. QoL data obtained using the Functional Assessment of Cancer Therapy-General questionnaire were converted to utilities. Costs and incremental cost-effectiveness ratios (ICERs) were reported in US dollars per quality-adjusted life year (QALY). Extensive 1-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis were performed. RESULTS: The least expensive strategy was sDC, which cost an average of $20,381, compared with cDC, which cost an average of $25,122. cDC had an ICER of $25,239 per QALY compared with sDC. cDC remained cost-effective, with an ICER <$50,000 per QALY, over a range of costs and estimates. In Monte Carlo sensitivity analysis using a $50,000 per QALY willingness-to-pay threshold, cDC was either dominant or cost-effective with an ICER <$50,000 per QALY in 83% of simulations. CONCLUSIONS: Combined weekly cDC appeared to be cost-effective compared with sDC as treatment strategy for patients with platinum-sensitive ovarian cancer, even when accounting for slightly lower QoL during treatment. Cancer 2012;118:386-

show abstract

Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report

Cited by 603 publications

References 87 publications

Cost effectiveness of guided Internet-based interventions for depression in comparison with control conditions: An individual-participant data meta-analysis

Cost effectiveness of guided Internet-based interventions for depression in comparison with control conditions: An individual-participant data meta-analysis

Cost Comparison Between Home Telemonitoring and Usual Care of Older Adults: A Randomized Trial (Tele-ERA)

Cost‐effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum‐sensitive, recurrent ovarian cancer

Contact Info

Product

Resources

About